A5110287659- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiation Therapy and Dosimetry
- PARP inhibition in cancer therapy
- Meningioma and schwannoma management
- Radiomics and Machine Learning in Medical Imaging
- Effects of Radiation Exposure
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Ocular Oncology and Treatments
- Childhood Cancer Survivors' Quality of Life
- Nonmelanoma Skin Cancer Studies
- Pituitary Gland Disorders and Treatments
- Cancer Treatment and Pharmacology
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oral and Maxillofacial Pathology
- Brain Tumor Detection and Classification
- DNA Repair Mechanisms
- Boron Compounds in Chemistry
- Bone Tumor Diagnosis and Treatments
- Melanoma and MAPK Pathways
- Genomics and Chromatin Dynamics
- Vascular Malformations Diagnosis and Treatment
Centre François Baclesse
2015-2025
Aliments Bioprocédés Toxicologie Environnements
2019-2025
Centre François Baclesse
2018-2024
Université de Bretagne Occidentale
2022
Université de Caen Normandie
2020-2021
Université de Rouen Normandie
2020-2021
Normandie Université
2020-2021
Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development new radiosensitizer crucial to improve patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be promising class radiosensitizer. aim this study evaluate Olaparib, PARPi,...
Despite continuous improvements in treatment of glioblastoma, tumor recurrence and therapy resistance still occur a high proportion patients. One underlying reason for this radioresistance might be the presence glioblastoma cancer stem cells (GSCs), which feature DNA repair capability. PARP protein plays an important cellular role by detecting damaged then activating signaling pathways that promote appropriate responses. Thus, inhibitors (PARPi) have recently emerged as potential...
The RANO-BM criteria, which employ a one-dimensional measurement of the largest diameter, are imperfect due to fact that lesion volume is neither isotropic nor homogeneous. Furthermore, this approach inherently time-consuming. Consequently, in clinical practice, monitoring patients trials compliance with criteria rarely achieved. objective study was develop and validate an AI solution capable delineating brain metastases (BM) on MRI easily obtain, using in-house solution, as well BM routine...
Inflammatory myofibroblastic tumors (IMTs) are known to be associated with rearrangements of the anaplastic lymphoma kinase (ALK) gene. The treatment this type tumor includes systemic therapies such as chemotherapies or anti-inflammatories; in recent years, targeted anti-ALK have emerged and became standard care ALK rearranged patients. We aimed present a rare case musculoskeletal IMT rearrangement, characterized by metastatic evolution enhanced responses sequential all ALK-TKI. outlined...
Abstract Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve outcomes. We implemented a phase 1-2a trial to assess safety and efficacy combined with standard radio-chemotherapy as in unresected patients. herein present results 1. Methods: Based on Stupp regimen, two sequential dose escalations were performed distinguish radiotherapy period maintenance for...
<p>A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>C. Progression-free (left) and overall (right) survival for first second olaparib dose-escalation cohorts of the trial. was defined as time elapsed from treatment start to RANO progression or death any cause (whichever occurs first); Overall cause.</p>
<p>B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) 60 months (bottom) after start of treatment in first line a partially resected glioblastoma patient.</p>
<div>AbstractPurpose:<p>Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa trial assess safety and efficacy combined with standard radiochemotherapy as in patients unresected GBM. herein present results I.</p>Patients Methods:<p>Based on Stupp regimen, two sequential dose escalations were performed...
Until 50% of patients with renal cancer or melanoma, develop brain metastases during the course their disease. Stereotactic radiotherapy has become a standard care for limited number metastases. Given radioresistant nature melanoma and cancer, optimization fractionation stereotactic is needed. The purpose this retrospective study was to elucidate if hypofractionated (HFSRT) impacts local control from tumors such as in comparison radiosurgery (SRS). Between 2012 2016, 193 metastases, smaller...
The optimal consolidation strategy for primary central nervous system lymphoma (PCNSL) remains controversial. Preventing radio-induced neurotoxicity of treatment through reduced-dose whole-brain radiotherapy (rdWBRT) at a dose 23.4 Gy is an interesting alternative to conventional WBRT in patients aged <60 years. From the LOC Network (Network Oculo-cerebral Lymphomas) database, we retrospectively selected with PCNSL years who showed complete (CR) or unconfirmed CR after high-dose...
Abstract Background Stereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from but controversial extracranial oligometastases. We assessed outcomes patients with metastases in oligometastatic, oligorecurrent, oligopersistent oligoprogressive settings (“oligometastatic spectrum”) under strategies using SBRT +/− systemic treatments. Methods A retrospective multicentric study consecutive adult 1–5 treated was conducted. Results Of 91...
Purpose: The aim of this study was to assess, in a large series, the efficacy and tolerance post-operative adjuvant hypofractionated stereotactic radiation therapy (HFSRT) for brain metastases (BMs). Methods materials: Between July 2012 January 2017, 160 patients from 2 centers were operated BM treated by HFSRT. Patients had between 1-3 BMs, no brainstem lesions or carcinomatous meningitis. primary endpoint local control. Secondary endpoints distant control, overall survival (OS) Results: 73...
Survival of childhood, adolescent and young adult (CAYA) cancers has increased with progress in the management treatments reached more than 80% at 5 years. Nevertheless, these survivors are great risk second non-malignant co-morbidities later life. DeNaCaPST is a non-interventional study whose aim to organize national screening for thyroid cancer breast CAYA cancers. It will compliance international recommendations, aim, regarding programme, offering every woman living France, equal risk, an...